Vitamin D metabolism and current options for therapeutic activation of vitamin D receptor in patients with chronic kidney disease or renal failure;Metabolizmus vitaminu D a současné možnosti terapeutické aktivace receptoru pro vitamin D při chronickém onemocnění a selhání ledvin

Vnitrni Lekarstvi

Volumn 58, Issue 11, 2012, Pages 839-849

  Dusilová Sulková, Sylvie ^a,b  

^a UNIVERSITY HOSPITAL HRADEC KRALOVE   (Czech Republic)

^b INSTITUTE FOR CLINICAL AND EXPERIMENTAL MEDICINE   (Czech Republic)

Author keywords

Calcidiol; Calcitriol; Chronic kidney disease; Chronic renal failure; Paricalcitol; Secondary hyperparathyroidism; Vitamin D receptor

Indexed keywords

CALCIDIOL 1 MONOOXYGENASE; CALCITRIOL; FIBROBLAST GROWTH FACTOR 23; PARATHYROID HORMONE; PARICALCITOL; VITAMIN D DERIVATIVE; VITAMIN D RECEPTOR; CALCITRIOL RECEPTOR; ERGOCALCIFEROL; VITAMIN D BINDING PROTEIN;

CALCIUM ABSORPTION; CHRONIC KIDNEY DISEASE; CHRONIC KIDNEY FAILURE; DISEASE ASSOCIATION; GASTROINTESTINAL TRACT; HUMAN; KIDNEY FUNCTION; PARATHYROID GLAND; PROGNOSIS; REVIEW; SECONDARY HYPERPARATHYROIDISM; VITAMIN D DEFICIENCY; VITAMIN D METABOLISM; METABOLISM;

CALCITRIOL; ERGOCALCIFEROLS; HUMANS; HYPERPARATHYROIDISM, SECONDARY; KIDNEY FAILURE, CHRONIC; RECEPTORS, CALCITRIOL; RENAL INSUFFICIENCY, CHRONIC; VITAMIN D-BINDING PROTEIN;

EID: 84870941470     PISSN: 0042773X     EISSN: 18017592     Source Type: Journal    
DOI: None     Document Type: Review

References (65)

1. Vitamin D (příloha). Vnitř Lék 2012; 58: 378-416.
2. Dusilová Sulková S et al. Renální osteopatie. Praha: Maxdorf Jessenius, 2007.
3. Dusilová Sulková S. Kostní choroba při selhání ledvin a její moderní terapie. Vnitř Lék 2011; 57: 620-625.
4. Rodriguez M, Lorenzo V. Parathyroid hormone, a uremic toxin. Semin Dial 2009; 22: 363-368.
5. Go AS, Chertow GM, Fan D et al. Chronic kidney disease and the risk of death, cardiovascular events and hospitalization. N Engl J Med 2004; 351: 1296-1305.
6. Panichi V, Bigazzi R, Paoletti S et al. (RISCAVID Study Group) Impact of calcium, phosphate, PTH abnormalities and management on mortality in hemodialysis: results from the RISCAVID study. J Nephrol 2010; 23: 556-562.
7. LaClair RE, Hellman RN, Karp SL et al. Prevalence of calcidiol deficiency in CKD: a cross-sectional study across latitudes in United States. Am J Kidney Dis 2005; 45: 1026-1033. (Pubitemid 40806515)
8. Levin A, Bakris GL, Molitch M et al. Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. Kidney Int 2007; 71: 31-38. (Pubitemid 44967731)
9. Jean G, Charra B, Chazot C. Vitamin D deficiency and associated factors in hemodialysis patients. J Ren Nutr 2008; 18: 395-399.
10. Ewers B, Gasbjerg A, Mølgaard Ch et al. Vitamin D status in kidney transplant patients: need for intensified routine supplementation. Am J Clin Nutr 2008; 87: 431-437. (Pubitemid 351226081)
11. Holick MF. Vitamin D deficiency. N Engl J Med 2007; 357: 266-281.
12. Nigwekar SU, Bhan I, Thadhani R. Ergocalciferol and cholecalciferol in CKD. Am J Kidney Dis 2012; 60: 139-156.
13. Ala-Houhala MJ, Vahavihu K, Hasan T. Narrow-band ultraviolet B exposure increases serum vitamin D levels in haemodialysis patients. Nephrol Dial Transplant 2012; 27: 2435-2440.
14. Michaud J, Naud J, Quimet D et al. Reduced hepatic synthesis of calcidiol in uremia. J Am Soc Nephrol 2011; 21: 1488-1497.
15. Dusso AS. Kidney disease and vitamin D levels: 25-hydroxyvitamin D, 1,25-dihydroxyvitamin D and VDR activation. Kidney Int 2011; 79: (Suppl. 1): 136-141.
16. Dusso AS, Tokumoto M. Defective renal maintenance of the vitamin D endocrine system impairs vitamin D renoprotection: a downeard spiral in kidney disease. Kidney Int 2011; 79: 715-729.
17. National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003; 42: (Suppl. 3): S1-S201.
18. Kidney Disease Improving Global Outcomes (KDIGO) CKD-MBD work group KDIGO clinical practice guideline for the diagnosis, evaluation, prevention and treatment of chronic kidney disease - mineral bone disorder (CKD-MBD). Kidney Int 2009; 76: (Suppl. 113): S1-S130.
19. Dusso AS, Brown AJ, Slatopolsky E. Vitamin D. Am J Physiol Renal Physiol 2005; 289: F8-F28.
20. Prie D, Friedlander G. Reciprocal control of 1,25-dihydroxyvitamin D and FGF-23 formation involving the FGF-23/Klotho system Clin J Am Soc Nephrol 2010; 5: 1717-1722.
21. Dusilová Sulková S, Kalousová M. Fibroblastový růstový faktor 23 (FGF-23, fibroblast growth factor 23) je molekulou s velkým významem pro klinickou, dialyzační i transplantační nefrologii - základní přehled současných poznatků. Aktuality v nefrologii 2011; 17: 17-22.
22. Sochorová K, Budinský V, Rožková D et al. Paricalcitol (19-nor-1,25dihydroxyvitamin D2) and calcitriol (1,25-dihydroxyvitamin D3) exert potent immunomodulatory effects on dendritic cells and inhibit induction of antigen-specific T cells. Clin Immunol 2009; 133: 69-77.
23. Patel T, Singh AK. Role of vitamin D in chronic kidney disease. Semin Nephrol 2009; 29: 113-121.
24. Andress DL. Vitamin D in chronic kidney disease: a systemic role for selective vitamin D receptor activation. Kidney Int 2006; 69: 33-43. (Pubitemid 43117736)
25. Bosworth CR, Levin G, Robinson-Cohen C et al. The serum 24,25-dihydroxyvitamin D concentration, a marker of vitamin D catabolism, is reduced in chronic kidney disease. Kidney Int 2012; doi:10.1038/ki.2012.193.
26. Lee CT, Ng HY, Lien YH et al. Effects of cyclosporine, tacrolimus and rapamycin on renal calcium transport and vitamin D metabolism. Am J Nephrol 2011; 34: 87-94.
27. Brown AJ, Coyne DV. Bioavailable vitamin D in chronic kidney disease. Kidney Int 2012; 82: 5-7.
28. Bhan I, Powe CE, Berg AH et al. Bioavailable vitamin D is more tightly linked to mineral metabolism than total vitamin D in incident hemodialysis patients. Kidney Int 2012; 82: 84-89.
29. London GM, Guerin AP, Marchais SJ et al. Arterial media calcification in end-stage renal disease: impact on all-cause and cardiovascular mortality. Nephrol Dial Transplant 2003; 18: 1731-1740. (Pubitemid 37098542)
30. Mizobuchi M, Towler D, Slatopolsky E. Vascular calcification: The killer of patients with chronic kidney disease. J Am Soc Nephrol 2009; 20: 1453-1464.
31. Rodriguez M, Martinez-Moreno JM, Rodriguez-Ortiz ME. Vitamin D and vascular calcification in chronic kidney disease. Kidney Blood Press Res 2011; 34: 261-268.
32. Garcia-Canton C, Bosch E, Ramirez A et al. Vascular calcification and 25-hydroxyvitamin D in non-dialysis patients with chronic kidney disease stages 4 and 5. Nephrol Dial Transplant 2011; 26: 2250-2256.
33. Thadhani R, Appelbaum E, Pritchett Y et al. Vitamin D therapy and cardiac structure and function in patients with chronic kidney disease: the PRIMO randomized controlled trial. J Am Med Assoc 2012; 307: 674-684.
34. Alborzi P, Patel NA, Peterson C et al. Paricalcitol reduces albuminuria and inflammation in chronic kidney disease: a randomized double-blind pilot trial. Hypertension 2008; 52: 249-255.
35. Agarwal R. Vitamin D, proteinuria, diabetic nephropathy and progression of CKD. Clin J Am Soc Nephrol 2009; 4: 1523-1528.
36. Liu LJ, Lv JC, Shi SF et al. Oral calcitriol for reduction of proteinuria in patients with IgA nephropathy: a randomized controlled trial. Am J Kidney Dis 2012; 59: 67-74.
37. de Zeeuw D, Agarwal R, Amdahl M et al. Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomized controlled trial. Lancet 2010; 376: 1543-1551.
38. Courbebaisse M, Souberbielle JC, Thervet E. Potential nonclassical effects of vitamin D in transplant recipients. Transplantation 2010; 89: 131-137.
39. Armas LAG, Andukuri R, Barger-Lux J et al. 25-hydroxyvitamin D response to cholekalciferol supplementation in hemodialysis. Clin J Am Soc Nephrol 2012; T: 1428-1434.
40. Cunningham J. Supplemental vitamin D: will do no harm and might do good. Nature Rev Nephrol 2009; 5: 614-615.
41. Kandula P, Dobre M, Schold JD et al. Vitamin D supplementation in chronic kidney disease: A systematic review and meta-analysis of observational studies and randomized controlled trials. Clin J Am Soc Nephrol 2011; 6: 50-62.
42. Jones G. Why Dialysis Patients Need Combination Therapy with Both Cholecalciferol and A Calcitriol Analogs. Semin Dial 2010; 23: 239-243.
43. Slatopolsky E, Weerts C, Thielan J et al. Marked suppression of secondary hyperparathyroidism by intravenous administration of 1,25- dihydroxycholecalciferol in uremic patients. J Clin Invest 1984; 74: 2136-2143. (Pubitemid 15197358)
44. Wu-Wong JR, Nakane M, Ma J et al. Effects of Vitamin D analogs on gene expression profiling in human coronary artery smooth muscle cells. Atherosclerosis 2006; 186: 20-28.
45. Martin JK, Gonzalez E, Lindgerg JS et al. Paricalcitol dosing according to body weight or severity of hyperparathyroidism: a double-blind, multicenter, randomized study. Am J Kidney Dis 2001; 38: (Supp. 5): S57-S63. (Pubitemid 33022207)
46. Cozzolino M, Brancaccio D. Emerging role for the vitamin D receptor activator (VDRA), paricalcitol, in the treatment of secondary hyperparathyroidism. Expert Opin Pharmacother 2008; 9: 947-954. (Pubitemid 351593742)
47. Ross EA, Tian J, Abboud H et al. Oral paricalcitol for the treatment of secondary hyperparathyroidism in patients on hemodialysis or peritoneal dialysis. Am J Nephrol 2008; 28: 97-106. (Pubitemid 350126499)
48. Coyne D, Acharva M, Qiu P et al. Paricalcitol capsule for the treatment of secondary hyperparathyroidism in stages 3 and 4 CKD. Am J Kidney Dis 2006; 47: 263-276. (Pubitemid 43121329)
49. Li YC. Vitamin D: roles in renal and cardiovascular protection. Curr Opin Nephrol Hypertens 2012; 21: 72-79.
50. Drechsler C, Verduijn M, Pilz S et al. Vitamin D status and clinical outcomes in incident dialysis patients: results from the NECOSAD study. Nephrol Dial Transplant 2011; 26: 1024-1032.
51. Wolf M, Shah A, Gutierrez O et al. Vitamin D levels and early mortality among incident hemodialysis patients. Kidney Int 2007; 72: 1004-1013. (Pubitemid 47530570)
52. Oksa A, Spustová V, Krivosíková Z et al. Effects of long-term cholecalciferol supplementation on mineral metabolism and calciotropic hormones in chronic kidney disease. Kidney Blood Press Res 2008; 31: 322-329.
53. Sulková S, Fořtová M, Uhrová J et al. Význam stanovení metabolitů vitaminu D u pacientů se sníženou funkcí ledvin. Vnitř Lék 2004; 50: 510-518.
54. Teng M, Wolf M, Lowrie E et al. Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med 2003; 349: 446-456. (Pubitemid 36910023)
55. Teng M, Wolf M, Ofsthun MN et al. Activated injectable vitamin D and hemodialysis survival: a historical cohort study. J Am Soc Nephrol 2005; 16: 1115-1125. (Pubitemid 41710323)
56. Kovesdy CP. Survival benefits with vitamin D receptor activation: New insights since 2003. Clin J Am Soc Nephrol 2010; 5: 1704-1709.
57. Naves-Díaz M, Alvarez-Hernández D, Passlick-Deetjen J et al. Oral active vitamin D is associated with improved survival in hemodialysis patients. Kidney Int 2008; 74: 1070-1078.
58. Shoben AB, Rudser KD, de Boer IH et al. Association of oral calcitriol with improved survival in nondialyzed CKD. J Am Soc Nephrol 2008; 19: 1613-1619.
59. Kalantar-Zadeh K, Kovesdy CP Clinical outcomes with active versus nutritional vitamin D compounds in chronic kidney disease. Clin J Am Soc Nephrol 2009; 4: 1529-1539.
60. Melamed ML, Thadhani RI. Vitamin D therapy in chronic kidney disease and end stage renal disease. Clin J Am Soc Nephrol 2012; 7: 358-365.
61. Cozzolino M, Brancaccio D, Cannella G et al. VDRA therapy is associated with improved survival in dialysis patients with serum intact PTH <=150 pg/mL: results of the Italian FARO Survey. Nephrol Dial Transplant 2012; 27: 3588-3594.
62. Kovesdy CP, Lu JL, Matakuaskas S et al. Paricalcitol versus ergocalciferol for secondary hyperparathyroidism in CKD stages 3 and 4: A randomized controlled trial. Am J Kidney Dis 2012; 59: 58-66.
63. Ketteler M, Martin KJ, Cozzolino M et al. Paricalcitol versus cinacalcet plus low-dose vitamin D for the treatment of secondary hyperparathyroidism in patients receiving haemodialysis: study design and baseline characteristics of the IMPACT SHPT study. Nephrol Dial Transplant 2012; doi:10.1093/ndt/gfr531.
64. Ketteler M, Martin KJ, Wolf M et al. Paricalcitol versus cinacalcet plus low-dose vitamin D therapy for the treatment of secondary hyperparathyroidism in patients receiving haemodialysis: Results of the IMPACT SHPT study. Nephrol Dial Transpant 2012; 27: 1942-1949.
65. Cheng J, Zhang W, Zhang X et al. Efficacy and safety of paricalcitol therapy for chronic kidney disease: A meta-analysis. Clin J Am Soc Nephrol 2012; 7: 391-400.